

Index

A

Age of onset, 19
Amyotrophic lateral sclerosis, 1, 15,
35, 55, 95, 105, 121, 141
Amyotrophy, 2
Astrocytes, 35
Atrophy, 2
Autocrine signaling mechanisms, 44
Axonal transport, 95
Axons, 97

B

Biomarkers, 105
Bone marrow mononuclear cells, 124
Brain-gut axis, 142
Bulbar onset, 4, 106

C

C9ORF72, 36, 108
Camptocormia, 5
Cell therapy, 121
Charcot disease, 2
Cholinergic transmission, 75
Clinical correlations, 150
Clinical course, 5
Clinical evidence, 150
Clinical features, 2
Clinical manifestation, 1

Clinical trials, 126
Cognitive errors, 21
Commensals, 146
Cortical, 69, 106
Corticospinal tract, 36

D

Decision-making algorithm, 28
Degenerative disorders, 2
Dementia, 2
Dextromethorphan/quinidine, 113
Diagnostic delay, 15
Differential diagnosis, 8
Disease phenotype, 18
Dysphagia, 11, 96, 144

E

Edaravone, 122
El Escorial classification, 9
Electrodiagnosis, 24
Electrodiagnostic testing, 23
Electrophysiological properties, 56
Embryonic development, 57
Embryonic stem cells, 122
Excitatory neurotransmission, 40
Excitatory transmission, 77
Exosomes, 110
Experimental models, 62
Extracellular RNAs, 110

F

Familial amyotrophic lateral sclerosis, 36
Frontotemporal dementia, 2
Frontotemporal lobar degeneration, 96
FUS, 96

G

GABA transporters, 40
GABAergic transmission, 66
Gastrointestinal, 141
Gender, 20
GGGGCC repeat expansions, 36
Glial activation, 36
Glutamate, 40
Glutamatergic inputs, 77
Glycinergic transmission, 66
Guam, 2

H

Heterogeneity, 36
hnRNPA1, 96
hnRNPA2/B1, 96

I

Inappropriate testing, 23
Incomplete testing, 23
Induced pluripotent stem cells, 128
Inflammation, 149
Inflammatory markers, 111
Inhibitory currents, 64
Inhibitory transmission, 66
Intracellular Ca²⁺, 44
Intraspinal injections, 127

J

Jaw reflex, 80

K

Kii Peninsula, 2

L

Laboratory investigations, 8
Lipids, 145
Local translation, 95, 99
Lou Gehrig disease, 2
Lower motor neurons, 36

M

Management, 1, 10
Mesenchymal stem cells, 122, 124
Metabolic dysfunction, 145
Metabolites, 112
Microbiome modulation, 150
Microbiota, 141
Minimizing diagnostic delay, 27
Misdiagnosis, 21
Mitochondrial biomarkers, 112
Modulatory transmission, 75
Monoaminergic systems, 76
Mononuclear cells, 123
Motoneuron excitability, 55
Motoneurons, 56
Motor neuron diseases, 2
Motor neuron, 2
Multipotent stem cells, 122
Muscular weakness, 2

N

Neural stem cells, 122, 126
Neurodegeneration, 146
Neuroendocrine mechanisms, 146
Neurofilaments, 109
Neuroimaging, 24
Neuroinflammation, 36, 124

Neuronal degeneration, 36
Neurons, 97
Neurotrophic factors, 44

O

Oropharyngeal, 12
Orally, 10

P

Palliative management, 11
Paracrine signaling mechanisms, 44
Parkinsonism, 2
Pathological features, 8
Patient comorbidities, 20
Patient-specific factors, 18
Pluripotent stem cells, 122
Postnatal development, 57
Preclinical models, 123
Primary lateral sclerosis, 6
Progranulin, 111
Progressive bulbar palsy, 5
Progressive muscular atrophy, 5
Proprioceptive system, 79
Proteomics, 111

Q

Quinidine, 11
Quality of life, 16, 27

R

Radiculopathy, 22
Ribosomal protein, 98
Riluzole, 122
RNA granules, 97
RNA-binding proteins, 97
RNAseq, 111

S

Sialorrhea, 11, 113
SOD1, 36, 56
Specialist referrals, 21
Spinal motor neurons, 106
Sporadic amyotrophic lateral sclerosis, 36
Stem cells, 122
Stress granules, 110
Subtypes, 2
Superoxide dismutase, 36
Surgical intervention, 24
Symptomatic management, 11
Synaptic transmission, 55

T

TARDBP, 96
TDP-43, 96, 109
Therapeutic approaches, 73, 150
Therapeutic strategies, 123
Time to diagnosis, 15
Totipotent stem cells, 122
Transport targets, 98

U

Ubiquitin, 8
Upper motor neuron, 3

V

Vascular endothelial growth factor, 40
Ventral horn, 36, 37
Vimentin, 38

W

Weakness, 3
West New Guinea, 2
Workup algorithm, 26

X

Xenogeneic, 125

Y

Younger populations, 19

Z

Zn²⁺

Doi: <https://doi.org/10.36255/exonpublications.amyotrophiclateralsclerosis.index.2021>